Patents Examined by Michael D. Pak
  • Patent number: 11123461
    Abstract: A method and device for localized treatment of tissues or organs that were exposed to ischemia and reperfusion (IR) injury, in order to reduce their structural damage and loss of function. The method further includes intra-arterial treatment of transplanted tissues or organs, which are exposed to similar damage of IR and are at risk of impaired function. Leptin antagonist is administered as a bolus injection directly into a re-opened artery, which supplies blood to the tissue or organ involved, immediately after reperfusion. In some cases, after administering a bolus injection of leptin antagonist, the effect of leptin antagonist in the involved organ can be prolonged by deploying a double function drug eluting stent, which elutes leptin antagonist into the lumen, e.g., by sustained release, while eluting antiproliferative drug into the vessel wall to prevent local stenosis, which may appear due to stent deployment.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: September 21, 2021
    Assignee: REMODELESS CV LTD
    Inventor: Jacob Schneiderman
  • Patent number: 11098117
    Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: August 24, 2021
    Assignee: Agenus Inc.
    Inventors: Yanping Xiao, Nicholas Stuart Wilson, Benjamin Maxime Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk, Dhan Sidhartha Chand, David Adam Savitsky, Dennis John Underwood, Olga Ignatovich
  • Patent number: 11092608
    Abstract: The invention relates to methods of identifying compounds that modulate mTORC1 activity in a cell by modulating the activity of CASTOR1, as well as to the use of such identified compounds in the modulation of mTORC1 and the treatment of diseases and conditions characterized by aberrant mTORC1 activity.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: August 17, 2021
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: David M. Sabatini, Lynne Chantranupong, Robert A. Saxton, Steven P. Gygi, Melanie P. Gygi
  • Patent number: 11091556
    Abstract: The present invention provides caninized human anti-human IL-4R? antibodies that have specific sequences and a high binding affinity for canine IL-4R?. The invention also relates to use of these antibodies in the treatment of dogs against atopic dermatitis.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: August 17, 2021
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang
  • Patent number: 11090363
    Abstract: Controlled release of VIP from PLGA microparticles was accomplished and varied through use of different polymer molecular sizes, addition of solutes to the inner aqueous phase, and use of our computer model. Released VIP from microparticles appeared to be bioactive and caused DCs to produce more CCL22 than DCs treated with blank particles at 7 and 24 hours. Additionally, DCs treated with VIP microparticle releasates recruited higher percentages of FoxP3+ T-cells in in vitro chemotaxis studies. Testing in a mouse model in vivo indicated that VIP microparticles have significant therapeutic potential to treat periodontal disease by reducing the bone loss in infected mice relative to the blank group.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: August 17, 2021
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Steven R. Little, Andrew Jason Glowacki
  • Patent number: 11084881
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: August 10, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla Henning, Michelle Minhua Han, Guodong Chen, Richard Huang, Indrani Chakraborty, Haichun Huang, Susan Wong, Huiming Li
  • Patent number: 11078286
    Abstract: Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: August 3, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Javed Khan, Sivasubramanian Baskar, Rimas J. Orentas, Dimiter S. Dimitrov, Zhongyu Zhu, Tai Chi Cheuk
  • Patent number: 11053319
    Abstract: The invention relates to CXCR2, to antibodies and related fragments thereof for binding to CXCR2, to production of said antibodies and fragments and to use of said antibodies and fragments for detection and therapy of various conditions.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: July 6, 2021
    Assignee: Monash University
    Inventors: Charles Reay Mackay, Remy Michel Robert
  • Patent number: 11033662
    Abstract: A method and device for localized treatment of tissues or organs that were exposed to ischemia and reperfusion (IR) injury, in order to reduce their structural damage and loss of function. The method further includes intra-arterial treatment of transplanted tissues or organs, which are exposed to similar damage of IR and are at risk of impaired function. Leptin antagonist is administered as a bolus injection directly into a re-opened artery, which supplies blood to the tissue or organ involved, immediately after reperfusion. In some cases, after administering a bolus injection of leptin antagonist, the effect of leptin antagonist in the involved organ can be prolonged by deploying a double function drug eluting stent, which elutes leptin antagonist into the lumen, e.g., by sustained release, while eluting antiproliferative drug into the vessel wall to prevent local stenosis, which may appear due to stent deployment.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: June 15, 2021
    Assignee: REMODELESS CV LTD
    Inventor: Jacob Schneiderman
  • Patent number: 11028177
    Abstract: The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising the same, and recombinant T cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: June 8, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, Carl H. June, Michael D. Kalos, Andreas Loew, John Scholler
  • Patent number: 11013790
    Abstract: Provided herein are vaccine compositions containing at least one retrievable biocompatible macrocapsule containing immuno-isolated allogeneic cells that secrete an immunomodulator such as GM-CSF (granulocyte-macrophage colony stimulating factor) and an antigenic component such as autologous tumor cells or infectious agents. Also provided are kits and pharmaceutical compositions containing the vaccine compositions as well as methods of use thereof for therapeutic or preventative vaccination against tumors or infectious agents.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: May 25, 2021
    Assignee: MaxiVAX SA
    Inventor: Nicolas Mach
  • Patent number: 11002728
    Abstract: It is an object to provide a method for evaluating a medicinal substance targeting a G protein-coupled receptor (GPCR). Specifically, the present invention relates to a method for evaluating the activity of a GPCR comprising a step of bringing a target substance into contact with a cell expressing a GPCR on the cell membrane; and a step of determining the diffusive dynamics of the GPCR on the cell membrane.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: May 11, 2021
    Assignee: RIKEN
    Inventors: Masataka Yanagawa, Yasushi Sako, Michio Hiroshima, Masato Yasui, Masahiro Ueda, Yuichi Togashi
  • Patent number: 10988545
    Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to GITR and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: April 27, 2021
    Assignee: Potenza Therapeutics, Inc.
    Inventors: Daniel Hicklin, Cynthia Seidel-Dugan, William Winston, Jose-Andres Salmeron-Garcia, Heather Brodkin, Sonja Kleffel, Nels P. Nielson
  • Patent number: 10973870
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: April 13, 2021
    Assignee: Ferring B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • Patent number: 10954284
    Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: March 23, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Anderson, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • Patent number: 10948480
    Abstract: This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing FR? immunity in a mammal are provided. This document also provides methods and materials related to stimulating immunity to folate receptors.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 16, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Keith L. Knutson, Lynn C. Hartmann, Kimberly R. Kalli, Christopher J. Krco
  • Patent number: 10927176
    Abstract: The present invention provides a tumor-specific anti-EGFR antibody and application thereof. The antibody can be used for preparing targeted antitumor drugs and tumor diagnosis drugs.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: February 23, 2021
    Assignee: CARSGEN THERAPEUTICS CO., LTD.
    Inventors: Huamao Wang, Bo Song
  • Patent number: 10913779
    Abstract: Provided herein are new compositions and methods to target pharmaceutical agents to pathological areas by utilizing fusion polypeptides. These fusion polypeptides contain two or more domains: (i) aptamer sequences that bind to exposed collagenous (XC-) proteins present in pathological areas, including cancerous and viral lesions, (ii) immunomodulators, such as cytokines, and optionally (iii) at least one linker joining the two domains or at the terminus of the polypeptide. In some cases, the linker is a rigid linker, e.g., a rigid helical linker. Also provided herein are methods of treating cancer and/or infectious diseases using the new fusion polypeptides.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: February 9, 2021
    Assignee: Counterpoint Biomedica LLC
    Inventors: Frederick L. Hall, Erlinda M. Gordon
  • Patent number: 10914736
    Abstract: The present invention relates to a nanovesicle comprising a heterodimeric G-protein coupled receptor, a method for preparing the nanovesicle, a field effect transistor-based taste sensor comprising the nanovesicle, and a method for manufacturing the taste sensor. The field effect transistor based taste sensor functionalized by the nanovesicle comprising the heterodimer G-protein coupled receptor according to the present invention has excellent sensitivity and selectivity and may highly specifically detect a sweet taste substance in real time, by using the heterodimeric G-protein coupled receptor and the nanovesicle comprising the same.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: February 9, 2021
    Assignee: Seoul National University R&DB Foundation
    Inventors: Tai Hyun Park, Seung Hun Hong, Hyun Seok Song, Hye Jun Jin, Sae Ryun Ahn
  • Patent number: 10906948
    Abstract: The present invention relates to non-naturally occurring, mutated Semaphorin 3 molecules. Particularly, the invention relates to the mutated Semaphorin 3 or the functional fragment thereof that exhibit improved properties and pharmacologic effects, e.g., in the treatment of angiogenic disease and cancer. In addition, the present invention relates to nucleic acid molecules encoding such polypeptides, and vectors and hosts comprising such nucleic acids. The invention further relates to methods for producing the polypeptides of the invention, and to methods of using them in the treatment of disease, in particular in the medical intervention of angiogenic diseases, tumors and/or cancer.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: February 2, 2021
    Assignee: Seagull Therapeutics SAS
    Inventors: Guido Serini, Enrico Giraudo, Luca Tamagnone